Dexcom, Inc. Enters Material Definitive Agreement

TL;DR

Dexcom just signed a big deal, details TBD.

AI Summary

On December 20, 2024, Dexcom, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as the counterparty or the financial terms involved.

Why It Matters

This filing indicates a significant new contract or partnership for Dexcom, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.

Key Players & Entities

• Dexcom, Inc. (company) — Registrant
• December 20, 2024 (date) — Date of Earliest Event Reported

FAQ

From the Filing

0001093557-24-000197.txt : 20241223 0001093557-24-000197.hdr.sgml : 20241223 20241223160542 ACCESSION NUMBER: 0001093557-24-000197 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241220 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20241223 DATE AS OF CHANGE: 20241223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 241573621 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20241220.htm 8-K dxcm-20241220 false 0001093557 0001093557 2024-12-20 2024-12-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2024 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. As previously disclosed, DexCom, Inc. (the “Company”) has been involved in global patent litigation with Abbott Diabetes Care, Inc. (“Abbott”) and its affiliates. Both the Company and Abbott have accused the other of infringing certain patents, and each party has filed counterclaims and actions to invalidate the other party’s patents. On December 20, 2024, the Company and Abbott entered into a settlement and patent cross license agreement (the “Agreement”) to resolve all outstanding patent litigation between the parties (the “Litigation”). Under the terms of the Agreement, the Company granted Abbott and its affiliates, and Abbott and its affiliates granted the Company and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications relating to analyte sensing, including